Hung Trinh’s Post

In antibody-related business news, Combotope Therapeutics ApS and CiMaas BV have jointly announced an oncology research and license option agreement. Under this agreement, CiMaas has the option to select three tumor glycoform protein targets, with the aim of discovering and developing next-generation CAR-NK and CAR-T antibody-based therapeutics for cancer treatment. The first selected target is the Mucin-1 tumor glycoform. CiMaas will provide funding for the preclinical and clinical development of these candidates up to clinical proof of concept. According to the agreement, CiMaas will provide Combotope Therapeutics with an upfront payment. Combotope Therapeutics will be eligible for potential milestone payments per therapeutic candidate exclusively licensed, developed and commercialized by CiMaas, as well as tiered royalties. https://lnkd.in/ePs5eAT5

IPO Lock of the week for next week - Oncology biotech Boundless Bio sets terms for $100 million IPO: Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors. The San Diego, California based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Boundless Bio would command a fully diluted market value of $396 million. Boundless Bio is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1, which manages ecDNA replication and transcription in cancer cells. BBI-355 is currently being studied in a first-in-human, Phase 1/2 trial in patients with oncogene amplified cancers, with preliminary data expected in the 2H24. Goldman Sachs, Leerink Partners, Piper Sandler, and Guggenheim Securities are the joint bookrunners on the deal.

Increased investments, exemplified by Novo Holdings' $105 million in Alentis Therapeutics, highlight the commitment to advancing ADC development. The global push for innovative cancer therapies is evident in the market's expansion, particularly in China, through collaborations and licensing agreements. This article introduces key players in the dynamic ADC field.

Mythic Therapeutics, Inc., a Hemi portfolio, presented promising preclinical data on MYTX-011, their innovative ADC therapy for cancer, at the AACR Annual Meeting. This investigational therapy targets cMET, showing increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels. MYTX-011's pH-sensitive design allows for broader efficacy across various cMET expression levels, demonstrating potent cytotoxicity in multiple cancer cell lines and increased delivery of the payload in vivo. These findings suggest MYTX-011's potential as a versatile therapeutic candidate for a wide range of cMET-expressing malignancies, currently being evaluated in clinical trials for NSCLC. "We’re pleased to present data that highlight the potential of MYTX-011 as a therapeutic candidate for treating multiple types of solid tumors that express cMET," said Brian Fiske, Ph.D., Chief Scientific Officer and Co-founder of Mythic. #HemiBio https://lnkd.in/ePJnnUQX

There's no denying that oncology has been a major focus for pharma companies lately. The past month of January 2024 has seen a flurry of activity in this area, with news and moves aplenty. Johnson & Johnson's acquisition of #Ambrx is a significant development, but there are plenty of other noteworthy moves to consider: * Merck Group acquisition of Harpoon Therapeutics * Boehringer Ingelheim partnering with 3T Biosciences * Blockbuster MSD´s #Keytruda receiving the FDA approval in combination with chemo-radiotherapy for cervical cancer * The partnership between AbbVie (while partnering with #ConcertAI and #Caris in Landmark Oncology) and Umoja Biopharma to advance the CAR-T Cell Therapy * Roche and MediLink Therapeutics collaboration to develeop next-gen cancer drug Which one do you think will have the most significant impact? #innovation #pharma #oncology

2023 in a Rearview Mirror: Ups and Downs of Oncology Drug Development As we bid farewell to 2023, let's reflect on the remarkable strides in oncological drug development that defined the past year. 🚀 👉 Bispecific Marvels Take Center Stage: From epcoritamab to glofitamab, the approval of CD3 × CD20 bispecifics in rapid succession showcased their potential in treating aggressive lymphomas. Talquetamab and elranatamab joined the fray, providing new hope for heavily pre-treated multiple myeloma patients. The field boasts an "embarrassment of riches" with BCMA × CD3 engagers in the pipeline. 💪 🌟 Platform Revolution: Big pharma rallied behind arming antibodies with therapeutic payloads. Pfizer's $43 billion acquisition of Seagen and Merck's $22 billion licensing deal with Daiichi Sankyo for ADCs underscored the industry's commitment. AI in drug discovery and mRNA cancer vaccines marked additional milestones, redefining the landscape. 🛠️ 🎯 Hitting the Bullseye: KRAS inhibitors, like adagrasib and divarasib, expanded their reach, promising new avenues in cancer treatment. The spotlight on CLDN18.2-targeted therapies, particularly zolbetuximab, showcased potential in gastric and gastroesophageal cancers. However, challenges persist in the CD47 inhibition landscape. 🎯 🌐 Checkpoint Inhibitors Navigate Challenges: Despite expanded indications, PD-1 blockers faced hurdles in certain cancer types. Trials in advanced prostate cancer and recurrent ovarian cancer revealed mixed results, urging a reevaluation of their efficacy. 🛑 🎉 New Approvals Bring Hope: Momelotinib for anemia in myelofibrosis, nirogacestat for desmoid tumors, and quizartinib targeting FLT3 gene duplications marked significant FDA approvals. Pirtobrutinib's non-covalent BTK inhibition and capivasertib's selective AKT inhibition showcased groundbreaking advancements in breast cancer treatments. 🌈 🧠 Brain Cancer Breakthroughs: Dabrafenib and trametinib's approval for pediatric low-grade gliomas and FDA's Project Renewal leading to expanded indications for temozolomide highlighted progress in brain cancer therapeutics. 🌌 🚀 The journey continues, with each achievement and setback propelling us forward in the relentless pursuit of transformative cancer therapies. Here's to a future where innovation brings healing and hope! 🌟👩⚕️👨⚕️ #OncologyInnovation #CancerResearch https://lnkd.in/gmYXfmpk

Accent Therapeutics Secures $75M Series C Funding for Groundbreaking Cancer Therapies Lexington-based biopharmaceutical company, Accent Therapeutics developing cutting-edge precision cancer therapies, has successfully concluded a $75 million Series C financing round, to advance its groundbreaking DHX9 inhibitor and potential best-in-class KIF18A inhibitor, addressing critical unmet needs in oncology targets. The funding, spearheaded by Mirae Asset Capital Life Science, underscores the industry’s confidence in Accent’s innovative approach […] The post Accent Therapeutics Secures $75M Series C Funding for Groundbreaking Cancer Therapies first appeared on USTechTimes - Leading Startup and Technology News in the United States . The post Accent Therapeutics Secures $75M Series C Funding for Groundbreaking Cancer Therapies appeared first on USTechTimes - Leading Startup and Technology News in the United States . https://lnkd.in/g7VeQDwN #USTech #Tech

📰 Moderna is doubling down in cancer vaccines and cell therapies with a new Immatics research partnership that could eventually top $1.7 billion in milestones. The deal will see the two companies work on mRNA-enabled in vivo expressed TCER molecules to create new cancer vaccines, bispecifics and cell therapies. Both companies will bring existing programs to the table and each will maintain ownership of their respective programs. Find more comments from Toni Weinschenk, PhD, Chief Innovation Officer at Immatics and Rose Loughlin, Ph.D., Moderna's Senior Vice President for Research and Early Development 👉 https://lnkd.in/gc_NusYQ #vaccines #cancer #researchanddevelopment #biotechnology #pharmaceuticals #pharmconnect

AbbVie has made a huge move recently buying ImmunoGen for a reported $10 billion! 🤩🤑 This milestone acquisition will bolster AbbVie's presence in the red hot Oncology segment, expanding its current portfolio of products related to cancer treatment💊 This latest move is further proof that AbbVie is looking to continue to grow its presence in this key therapeutic area. This acquisition is just the latest in a line of strategic acquisitions and investments as AbbVie looks to drive growth and success in this increasingly competitive space 🤝 Partnering with ImmunoGen keeps AbbVie on the successful path of growth in cancer therapeutics, offering new and innovative treatments for some of the long standing needs in the field 🤝👍 #Oncology #Biotechnology #InnovativeTherapeutics #ClinicalResearch #ClinicalTrial #BiotechAquisition #AbbVie #LifeScienceNews #ElixirAssociates #StaffingPartner

In business news, Pierre Fabre Group announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of a biotechnology company allows Pierre Fabre Laboratories to add VERT-002 to its oncology discovery pipeline. VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET. This target is a known disease driver in patients suffering from Non-Small Cell Lung Cancer with mutations or amplification of MET. Deal terms were not disclosed. VERT-002 is in preclinical studies, with the first-in-human studies expected to begin in 2024. https://lnkd.in/ev5f9EDF.